StockNews.AI
XGN
StockNews.AI
175 days

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

1. Exagen to release 2024 Q4 and annual financial results. Conference call scheduled March 11. 2. CEO and CFO will present results. Results follow a routine earnings timeline. 3. Replay and dial-in details provided. Standard investor communication for autoimmune diagnostics.

4m saved
Insight
Article

FAQ

Why Neutral?

Earnings announcements traditionally trigger mixed short-term reactions. Historical earnings events have varied impacts depending on surprises in performance.

How important is it?

Regular earnings releases are key for updating valuation and expectations. Although no unexpected news is disclosed, the event remains important for near-term price adjustments.

Why Short Term?

The announcement is expected to influence trading around the release. Past similar earnings reports have primarily driven immediate volatility.

Related Companies

IDXXLH
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market opens on Tuesday, March 11, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 AM ET (5:30 AM PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com. A replay of the conference call will be available until Monday, April 14, 2025, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay by dialing 201-612-7415 (U.S.) or +1-877-660-6853 (international) using passcode 13751928. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes. About Exagen Inc. Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visit Exagen.com or follow @ExagenInc on X. Contact:Ryan DouglasExagen Inc.ir@exagen.com760.560.1525

Related News